Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glucose Abnormalities Clear all
Completed Phase 2 Interventional

Leptin to Treat Severe Insulin Resistance - Pilot Study

NCT00027456
View directory record Official record
Conditions
Syndrome
Interventions
Leptin A-100
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Oral Glucose Tolerance Testing Using Candy for Cystic Fibrosis

NCT04579939
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Candy Glucose Tolerance Test
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
10 Years to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated No phase listed Observational

Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature

NCT00121875
View directory record Official record
Conditions
Turner Syndrome, Idiopathic Short Stature
Interventions
somatropin (rDNA)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 14 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2009 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Influence of Endothelial Function on Central and Peripheral Causes Of Exercise Impairment in Type 2 Diabetes

NCT00786019
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exercise program, Ascorbic Acid (Vitamin C)
Behavioral · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
30 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 11, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 4 Interventional

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

NCT06674109
View directory record Official record
Conditions
Gout and Hyperuricemia
Interventions
Empagliflozin 10 mg, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Trial of Leptin Replacement Therapy in Patients With Lipodystrophy

NCT00896298
View directory record Official record
Conditions
Hypoleptinemia, Generalized Lipodystrophy, Partial Lipodystrophy, Insulin Resistance
Interventions
Leptin, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Not applicable Interventional

Extended Criteria For Fetal Myelomeningocele Repair

NCT02664207
View directory record Official record
Conditions
Obesity, Myelomeningocele, Pregnancy, Diabetes Mellitus in Pregnancy, Fetal Anomaly
Interventions
Open Fetal Repair of Myelomeningocele
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Biological Sample Collection for Research and Biobanking

NCT04270604
View directory record Official record
Conditions
Parkinson Disease, Diabetes Mellitus, Type 1, Macular Degeneration, ALS, Cancer, Alzheimer Disease, Huntington Disease
Interventions
Biological sample collection
Other
Lead sponsor
New York Stem Cell Foundation Research Institute
Other
Eligibility
1 Month to 100 Years
Enrollment
1,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Not applicable Interventional

Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)

NCT02052479
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS
Interventions
Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)
Other
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2019 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 4 Interventional Results available

Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

NCT00231894
View directory record Official record
Conditions
Diabetes, Schizophrenia, Insulin Resistance, Cognitive Impairment
Interventions
Pioglitazone, Life style diet group, Placebo
Drug · Behavioral · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 70 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2017 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2Phase 3 Interventional

Dextrose Gel Does Not Prevent Neonatal Hypoglycemia

NCT02523222
View directory record Official record
Conditions
Hypoglycemia, Infant, Small for Gestational Age, Premature Birth of Newborn, Fetal Macrosomia, Intrauterine Growth Restriction, Complication of Prematurity, Neonatal Hypoglycemia
Interventions
40% Dextrose gel
Dietary Supplement
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 1 Hour
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Williams Syndrome Strength, Hormones, Activity & Adiposity, DNA Programming, Eating Study

NCT03758651
View directory record Official record
Conditions
Williams Syndrome, Lipedema
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting No phase listed Observational

Continuous Glucose Monitoring and OGTT Screen for Cystic Fibrosis Related Diabetes in Cystic Fibrosis

NCT06560463
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis
Interventions
Access to Dexcom G7 CGM Data
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Not yet recruiting Phase 3 Interventional

The Ultrasound-Guided Dextrose Prolotherapy in Ehlers-Danlos Syndrome Patients

NCT05279937
View directory record Official record
Conditions
Ehlers-Danlos Syndrome, Low Back Pain, Sacroiliac Instability
Interventions
Dextrose 50% Intravenous Solution, Lidocaine 1% Injectable Solution
Drug
Lead sponsor
Tulane University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Not applicable Interventional

MD2Me - Texting to Promote Chronic Disease Management

NCT01253733
View directory record Official record
Conditions
Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
Interventions
MD2ME
Behavioral
Lead sponsor
Huang, Jeannie, M.D.
Individual
Eligibility
14 Years to 22 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jan 25, 2016 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Proteins in Disease and Health

NCT00100204
View directory record Official record
Conditions
Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Phase 2 Interventional

GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance

NCT04731272
View directory record Official record
Conditions
Cystic Fibrosis, Pancreatic Insufficiency, Abnormal Glucose Tolerance, Diabetes
Interventions
Dulaglutide 0.75Mg/0.5Ml Inj Pen
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed Phase 2 Interventional

Inositol Supplementation to Treat PCOS (INSUPP-PCOS)

NCT03864068
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Anovulation, Hyperandrogenism, Insulin Resistance, Glucose Intolerance, Metabolic Complication
Interventions
Placebo, Inositol
Other · Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glycemic Monitoring in Cystic Fibrosis

NCT02211235
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 25 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 23, 2026, 5:00 PM EDT
Not yet recruiting Phase 2 Interventional

Verapamil Effect in Cystic Fibrosis-related Dysglycemia

NCT07688070
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis (CF), Abnormal Glucose Tolerance
Interventions
Verapamil Hydrochloride
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Recruiting Not applicable Interventional

CGM Dynamic Index for Predicting Prediabetes in Cystic Fibrosis

NCT06642610
View directory record Official record
Conditions
Prediabetes, Cystic Fibrosis (CF), Cystic Fibrosis-related Diabetes
Interventions
CGM Dynamic Index (CDI)
Device
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated No phase listed Observational

Glucose Homeostasis in Pseudohypoparathyroidism

NCT03761290
View directory record Official record
Conditions
Pseudohypoparathyroidism and Pseudopseudohypoparathyroidism, Pseudohypoparathyroidism Type Ia, Albright Hereditary Osteodystrophy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 50 Years
Enrollment
14 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Jul 23, 2026, 5:00 PM EDT
Terminated Phase 1 Interventional Results available

A Research Trial of Aralast in New Onset Diabetes (RETAIN)

NCT01183468
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 23, 2026, 5:00 PM EDT
Withdrawn Not applicable Interventional

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

NCT05229640
View directory record Official record
Conditions
CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions
Fibroscan
Device
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Jul 23, 2026, 5:00 PM EDT